Josh Jennings
Stock Analyst at Morgan Stanley
(2.55)
# 2,058
Out of 5,182 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $19.17 | +176.47% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $193.62 | +54.94% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $5.53 | +261.66% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $17.08 | +268.85% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.64 | +993.75% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $81.53 | -50.94% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $19.17
Upside: +176.47%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $193.62
Upside: +54.94%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $5.53
Upside: +261.66%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $17.08
Upside: +268.85%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.64
Upside: +993.75%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $81.53
Upside: -50.94%